Engstrøm, T., Kelbæk, H., Helqvist, S., Høfsten, D. E., Kløvgaard, L., Holmvang, L., . . . Køber, L. (2015). Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): An open-label, randomised controlled trial. The Lancet (British edition), 386(9994), 665-671. https://doi.org/10.1016/S0140-6736(15)60648-1
Citace podle Chicago (17th ed.)Engstrøm, Thomas, et al. "Complete Revascularisation Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease (DANAMI-3—PRIMULTI): An Open-label, Randomised Controlled Trial." The Lancet (British Edition) 386, no. 9994 (2015): 665-671. https://doi.org/10.1016/S0140-6736(15)60648-1.
Citace podle MLA (9th ed.)Engstrøm, Thomas, et al. "Complete Revascularisation Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease (DANAMI-3—PRIMULTI): An Open-label, Randomised Controlled Trial." The Lancet (British Edition), vol. 386, no. 9994, 2015, pp. 665-671, https://doi.org/10.1016/S0140-6736(15)60648-1.